Edward Garon
Expertise in
10
conditions

Dr. Edward Garon

Oncology
Premiere Oncology A Medical Corporation
2020 Santa Monica Blvd Ste 600, 
Santa Monica, CA 
Offers Telehealth
Expertise in
10
conditions
Premiere Oncology A Medical Corporation
2020 Santa Monica Blvd Ste 600, 
Santa Monica, CA 

Overview

Edward Garon is an Oncologist in Santa Monica, California. Dr. Garon is highly rated in 10 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

His clinical research consists of co-authoring 224 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in CA

Hospital Affiliations

Ronald Reagan UCLA Medical Center
Santa Monica - UCLA Med Ctr & Orthopaedic Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

Premiere Oncology A Medical Corporation
2020 Santa Monica Blvd Ste 600, Santa Monica, CA 90404
Other Locations
The Regents of the University of California
200 Medical Plz, Los Angeles, CA 90095

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2026
Intervention Type: Drug
Study Drugs: Ramucirumab, Erlotinib, Gefitinib, Osimertinib
Study Phase: Phase 3
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: April 08, 2025
Intervention Type: Drug
Study Drugs: M7824, Pembrolizumab
Study Phase: Phase 3
A Phase I Trial of Intratumoral Administration of CCL21-Gene Modified Dendritic Cell (Ad-CCL21-DC) Combined With Intravenous Pembrolizumab for Advanced NSCLC
A Phase I Trial of Intratumoral Administration of CCL21-Gene Modified Dendritic Cell (Ad-CCL21-DC) Combined With Intravenous Pembrolizumab for Advanced NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2025
Intervention Type: Biological
Study Drugs: Autologous Dendritic Cell-Adenovirus CCL21 Vaccine, Pembrolizumab
Study Phase: Phase 1
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
A Randomized, Open-label, Phase II Study of Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Subjects With Resectable Non-small Cell Lung Cancer (CANOPY-N)
A Randomized, Open-label, Phase II Study of Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Subjects With Resectable Non-small Cell Lung Cancer (CANOPY-N)
Enrollment Status: Terminated
Publish Date: June 20, 2024
Intervention Type: Drug
Study Drugs: Canakinumab, Pembrolizumab
Study Phase: Phase 2
A Phase II, Multicenter Study of Oral MET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
A Phase II, Multicenter Study of Oral MET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Enrollment Status: Completed
Publish Date: March 20, 2024
Intervention Type: Drug
Study Drug: INC280
Study Phase: Phase 2
A Phase III Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib in Combination With Osimertinib Versus Platinum - Pemetrexed Based Doublet Chemotherapy in Patients With Locally Advanced or Metastatic NSCLC Harboring EGFR Activating Mutations Who Have Progressed on Prior Generation EGFR-TKI Therapy and Whose Tumors Are T790M Mutation Negative and Harbor MET Amplification (GEOMETRY-E)
A Phase III Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib in Combination With Osimertinib Versus Platinum - Pemetrexed Based Doublet Chemotherapy in Patients With Locally Advanced or Metastatic NSCLC Harboring EGFR Activating Mutations Who Have Progressed on Prior Generation EGFR-TKI Therapy and Whose Tumors Are T790M Mutation Negative and Harbor MET Amplification (GEOMETRY-E)
Enrollment Status: Terminated
Publish Date: March 05, 2024
Intervention Type: Drug
Study Drugs: Capmatinib, Pemetrexed, Cisplatin, Carboplatin, Osimertinib
Study Phase: Phase 3
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: January 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: M7824, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin
Study Phase: Phase 2
Phase Ib, Multicenter, Open Label Study of PDR001 in Combination With Platinum Doublet Chemotherapy and Other Immunooncology Agents in PD-L1 Unselected, Metastatic NSCLS Patients (ElevatION:NSCLC-101 Trial)
Phase Ib, Multicenter, Open Label Study of PDR001 in Combination With Platinum Doublet Chemotherapy and Other Immunooncology Agents in PD-L1 Unselected, Metastatic NSCLS Patients (ElevatION:NSCLC-101 Trial)
Enrollment Status: Terminated
Publish Date: August 15, 2022
Intervention Type: Drug
Study Drugs: PDR001, Cisplatin, Gemcitabine, Pemetrexed, Carboplatin, Paclitaxel, Canakinumab
Study Phase: Phase 1
A Phase II Study of Pembrolizumab in EGFR Mutant, Tyrosine Kinase Inhibitor Naïve Treatment Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Phase II Study of Pembrolizumab in EGFR Mutant, Tyrosine Kinase Inhibitor Naïve Treatment Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: July 14, 2021
Intervention Type: Other, Biological
Study Phase: Phase 2
View 9 Less Clinical Trials

224 Total Publications

Differences in Clinical Trial Availability vs Distribution of Disease Among Gynecological Cancers.
Differences in Clinical Trial Availability vs Distribution of Disease Among Gynecological Cancers.
Journal: Oncology (Williston Park, N.Y.)
Published: December 10, 2025
Similar Doctors
Gary Schiller
Expertise in
65
conditions
Dr. Gary Schiller
Oncology
Expertise in
65
conditions
Dr. Gary Schiller
Oncology

UCLA Health Bowyer Oncology Center

200 UCLA Medical Plz Ste 120, 
Los Angeles, CA 
 (3.6 miles away)
310-206-6745
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gary Schiller is an Oncologist in Los Angeles, California. Dr. Schiller is highly rated in 65 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
27
conditions
Dr. Zev Wainberg
Oncology
Expertise in
27
conditions
Dr. Zev Wainberg
Oncology

Premiere Oncology A Medical Corporation

2020 Santa Monica Blvd Ste 600, 
Santa Monica, CA 
 (0.4 miles away)
310-829-5471
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Zev Wainberg is an Oncologist in Santa Monica, California. Dr. Wainberg is highly rated in 27 conditions, according to our data. His top areas of expertise are Gastroesophageal Junction Cancer, Pancreatic Cancer, Stomach Cancer, Pancreaticoduodenectomy, and Pancreatectomy.

Expertise in
31
conditions
Dr. Mark Agulnik
Oncology
Expertise in
31
conditions
Dr. Mark Agulnik
Oncology

USC Norris Comprehensive Cancer Center And Hospital

1441 Eastlake Ave, 
Los Angeles, CA 
 (15.9 miles away)
323-865-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Agulnik is an Oncologist in Los Angeles, California. Dr. Agulnik is highly rated in 31 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Synovial Sarcoma, Angiosarcoma, Osteotomy, and Colonoscopy.

Frequently Asked Questions about Dr. Edward Garon

How do I make an appointment with Dr. Edward Garon?

You can book an appointment with Dr. Edward Garon by calling their office at 310-829-5471. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Edward Garon a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Edward Garon is classified as an Elite expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Edward Garon specialize in?

While Dr. Edward Garon is a Oncology, they have specific expertise in Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Edward Garon participate in research or clinical trials?

Yes. Dr. Edward Garon has published 224 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Dr. Edward Garon's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Edward Garon accept my insurance?

Dr. Edward Garon accepts most major insurance plans, including Blue Shield of California and Cigna. We recommend calling the office directly at 310-829-5471 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Garon's expertise for a condition
ConditionClose
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile